A brain-derived MeCP2 complex supports a role for MeCP2 in RNA processing. Issue 5 (21st April 2011)

• Record Type: Journal Article
• Authors: Long, Steven W.; Ooi, Jenny Y. Y.; Yau, Peter M.; Jones, Peter L.
• Is Part Of: Bioscience reports. Volume 31:Issue 5(2011)
• Page Start: 333
• Page End: 343
• Publication Date: 2011-04-21
• Subjects: methyl CpG-binding domain (MBD) -- methyl-CpG-binding protein 2 (MeCP2) -- pre-mRNA processing factor 3 (Prpf3) -- Rett syndrome -- RNA; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20100124
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract : Mutations in MECP2 (methyl-CpG-binding protein 2) are linked to the severe postnatal neurodevelopmental disorder RTT (Rett syndrome). MeCP2 was originally characterized as a transcriptional repressor that preferentially bound methylated DNA; however, recent results indicate MeCP2 is a multifunctional protein. MeCP2 binding is now associated with certain expressed genes and involved in nuclear organization as well, indicating that its gene regulatory function is context-dependent. In addition, MeCP2 is proposed to regulate mRNA splicing and a mouse model for RTT shows aberrant mRNA splicing. To further understand MeCP2 and potential roles in RTT pathogenesis, we have employed a biochemical approach to identify the MeCP2 protein complexes present in the mammalian brain. We show that MeCP2 exists in at least four biochemically distinct pools in the brain and characterize one novel brain-derived MeCP2 complex that contains the splicing factor Prpf3 (pre-mRNA processing factor 3). MeCP2 directly interacts with Prpf3 in vitro and in vivo and many MECP2 RTT truncations disrupt the MeCP2–Prpf3 complex. In addition, MeCP2 and Prpf3 associate in vivo with mRNAs from genes known to be expressed when their promoters are associated with MeCP2. These results support a role for MeCP2 in mRNA biogenesis and suggest an additional mechanism for RTT pathophysiology.